Donald Taylor, MD
Pain Medicine · Marietta, GANPI 1023127875
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,841 of the $8,853 with a category attached, or 88.6%. It is spread thinly across 49 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations.
Across 435 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Orexo US, Inc.$1K
- AbbVie$953
- Indivior Inc.$864
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$678
- Pfizer$663
- Braeburn Inc.$592
- plus $4K from 43 others
Across 1 payment — averaging $580.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hikma Pharmaceuticals USA$580
What the payments were for
- Consulting fees$1,00011%
- Food & beverage$7,84189%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,853 in reported general payments places this provider in the 85th percentile of 203 pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 253 | $312,788 |
| OxycontinOxycodone Hcl | 195 | $248,935 |
| BelbucaBuprenorphine Hcl | 112 | $98,712 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 82 | $84,891 |
| Nucynta ErTapentadol Hcl | 39 | $71,942 |
| Buprenorphine | 244 | $62,457 |
| SublocadeBuprenorphine | 30 | $62,357 |
| Oxymorphone Hcl ErOxymorphone Hcl | 40 | $49,104 |
| LinzessLinaclotide | 82 | $46,568 |
| Nurtec OdtRimegepant Sulfate | 32 | $45,489 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 234 | $43,298 |
| NucyntaTapentadol Hcl | 32 | $41,486 |
| Fentanyl | 191 | $40,102 |
| UbrelvyUbrogepant | 24 | $35,633 |
| Oxycodone Hcl | 1,068 | $26,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er, Nucynta | $288 | $524,928436 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl | $93 | $119,171830 claims |
| Indivior Inc.Sublocade, Suboxone | $864 | $86,25966 claims |
| Orexo US, Inc.Zubsolv | $1,313 | $84,89182 claims |
| AbbVieLinzess, Ubrelvy | $953 | $82,202106 claims |
| PfizerNurtec Odt | $663 | $45,48932 claims |
| MerckBelsomra | $222 | $16,09937 claims |
| Redhill Biopharma Inc.Movantik | $67 | $12,82627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 203 pain medicine providers in Georgia.
Other pain medicine in Marietta
- Harsh DangariaMarietta$18K
- Lee TianMarietta$15K
- Rutvij ShahColumbus$86K
- Siddardth UmapathyFort Eisenhower$41K
- Susheel DuaAtlanta$36K
- Subodh AgrawalAthens$34K
- Jose MathewLawrenceville$27K
- Zhuo SunAugusta$26K
- Maged HamzaGainesville$24K
- Ankur PatelGainesville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.